Aaron Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Aaron Wealth Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,543	Closed	-$507K	–	696
2025 Q4	$507K	Sell	23,543 -54	-0.2%	-$1.05K	0.03%	431
2025 Q3	$360K	Hold	23,597	–	–	0.02%	488
2025 Q2	$209K	Buy	23,597 +955	+4%	+$8.39K	0.02%	463
2025 Q1	$177K	Hold	22,642	–	–	0.02%	440
2024 Q4	$238K	Hold	22,642	–	–	0.03%	378
2024 Q3	$297K	Hold	22,642	–	–	0.04%	307
2024 Q2	$318K	Hold	22,642	–	–	0.04%	226
2024 Q1	$382K	Hold	22,642	–	–	0.05%	191
2023 Q4	$320K	Hold	22,642	–	–	0.05%	184
2023 Q3	$233K	Hold	22,642	–	–	0.03%	226
2023 Q2	$373K	Hold	22,642	–	–	0.05%	183
2023 Q1	$207K	Buy	22,642 +10,000	+79%	+$82.2K	0.03%	239
2022 Q4	$90.5K	Buy	+12,642	New	+$88.6K	0.01%	239

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Aaron Wealth Advisors's AVDL Position: Q1 2026 in Review

Aaron Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 23,543 shares — an estimated $507K sold.

Aaron Wealth Advisors first reported a position in AVDL in Q4 2022 and held it in 13 quarters. The position peaked at $507K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Aaron Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Aaron Wealth Advisors sold 23,543 Avadel Pharmaceuticals shares in Q1 2026, an estimated $507K.
Aaron Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q4 2022 and held it in 13 quarters.
Aaron Wealth Advisors's Avadel Pharmaceuticals position peaked at $507K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Aaron Wealth Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.